soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). ⁣ ⁣ #ACC25 #Cardiology #ClinicalTrials #NEJM semaglutide soul trial oral cardiovascular

PEGylation the conjugation of polyethylene glycol chains to the peptide extends this half-life substantially, to several hours, enabling stable receptor engagement over experimental time windows that native MGF cannot sustain

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has garnered significant attention for its effectiveness in managing type 2 diabetes and promoting weight loss

Both drugs were titrated to maximum tolerated dose (tirzepatide 10 or 15 mg weekly

Not only does losing weight reduce your risk of sleep apnoea and improve related sleep symptoms , but it can also improve sleep in people without sleep apnoea

503(b) compounding pharmacies can produce large batches of compounded drugs during shortages, operating under FDA oversight that permits this production when commercially available alternatives do not exist

Other telehealth firms and compounders are playing it safe, ceasing sales altogether